What question did this study set out to answer?

This research aims to explore the clinical implications and management strategies after discontinuing GLP-1 receptor agonists.

March 29, 2026Diabetes Obesity and Metabolism8 citations

Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists

View Full Paper

ESE Abu ShahKoç University RARama AlShiabKoç University AAAnas AbdoKoç University

Key Points

This research aims to explore the clinical implications and management strategies after discontinuing GLP-1 receptor agonists.
Analysis of clinical transitions associated with GLP-1RA discontinuation
Evaluation of cardiometabolic outcomes
Recommendations for structured follow-up and multidisciplinary care
Weight regain is likely after stopping GLP-1RA treatment
Cardiometabolic benefits may diminish without appropriate management
Structured follow-up is crucial to maintain health improvements

Abstract

GLP-1RA discontinuation should be considered a high-risk clinical transition rather than a treatment endpoint. Structured follow-up and multidisciplinary management are essential to preserve long-term cardiometabolic benefits.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists

Key Points

Abstract

Cite This Study